Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -0.69% and Operating profit at -124.23% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 10.19% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -0.69% and Operating profit at -124.23% over the last 5 years
3
The company has declared Negative results for the last 11 consecutive quarters
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.8%
0%
22.8%
6 Months
10.34%
0%
10.34%
1 Year
23.58%
0%
23.58%
2 Years
-44.92%
0%
-44.92%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.69%
EBIT Growth (5y)
-124.23%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.38
Tax Ratio
12.27%
Dividend Payout Ratio
23.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.26%
ROE (avg)
10.19%
Valuation key factors
Factor
Value
P/E Ratio
129
Industry P/E
Price to Book Value
0.15
EV to EBIT
18.99
EV to EBITDA
-1.87
EV to Capital Employed
-0.10
EV to Sales
-0.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
0.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
446.40
469.70
-4.96%
Operating Profit (PBDIT) excl Other Income
39.10
49.40
-20.85%
Interest
3.80
3.30
15.15%
Exceptional Items
-2.90
-4.50
35.56%
Consolidate Net Profit
-15.20
4.60
-430.43%
Operating Profit Margin (Excl OI)
-24.30%
7.00%
-3.13%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -4.96% vs -4.24% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -430.43% vs 1,433.33% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,760.60
2,041.50
-13.76%
Operating Profit (PBDIT) excl Other Income
214.90
216.60
-0.78%
Interest
13.70
14.80
-7.43%
Exceptional Items
5.40
4.10
31.71%
Consolidate Net Profit
51.50
87.20
-40.94%
Operating Profit Margin (Excl OI)
18.70%
27.10%
-0.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -13.76% vs -0.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -40.94% vs -79.94% in Dec 2023
About Hubei Hongyuan Pharmaceutical Technology Co., Ltd. 
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
Specialty Chemicals
No Details Available.
Company Coordinates 
No Company Details Available






